

Supplementary Table 7. Patient outcomes according to systemic inflammation-related biomarkers

Outcome	Total (n = 1,500)	Quartiles of platelet-to-albumin ratio				Quartiles of neutrophil-platelet score				p for trend
		Q1 (n = 375)	Q2 (n = 376)	Q3 (n = 374)	Q4 (n = 375)	Q1 (n = 375)	Q2 (n = 375)	Q3 (n = 375)	Q4 (n = 375)	
28-day mortality	940 (62.7)	287 (76.5)	246 (65.4)	211 (56.4)	196 (52.3)	267 (71.2)	223 (59.5)	223 (59.5)	227 (60.5)	<0.001
90-day mortality	1,048 (69.9)	306 (81.6)	276 (73.4)	240 (64.2)	226 (60.3)	286 (76.3)	255 (68.0)	257 (68.5)	250 (66.7)	<0.001
CKRT duration (day)	3.0 (1.0-6.0)	3.0 (1.0-6.0)	3.0 (1.0-7.0)	3.0 (1.0-7.0)	3.0 (1.0-6.0)	2.0 (1.0-5.0)	3.0 (1.0-8.0)	3.0 (1.0-7.0)	3.0 (1.0-6.0)	0.07
KRT dependence at discharge ^a	70 (16.4)	2 (4.5)	15 (16.5)	25 (19.8)	27 (18.8)	14 (17.1)	19 (17.3)	22 (19.6)	15 (12.1)	<0.001
Length of ICU stay (day)	7.0 (3.0-16.0)	6.0 (2.0-14.0)	8.0 (3.0-21.0)	8.0 (3.0-17.0)	8.0 (3.0-17.0)	6.0 (2.0-12.0)	8.0 (3.0-20.0)	9.0 (3.0-21.0)	8.0 (3.0-16.0)	<0.001
Length of hospital stay (day)	22.0 (8.0-49.0)	21.0 (8.0-44.0)	22.0 (7.0-52.5)	25.0 (9.0-53.0)	21.0 (8.0-45.0)	16.0 (6.0-37.0)	25.0 (8.0-59.0)	27.0 (10.0-55.0)	22.0 (9.0-44.0)	0.007

Data are expressed as number (%) or median (interquartile range).

CKRT, continuous kidney replacement therapy; ICU, intensive care unit; KRT, kidney replacement therapy.

^aKRT dependence at discharge was defined as a patient being discharged without mortality and receiving KRT within 1 day before discharge.